#	Pagina
attuale pagina	/open-h2020/projects/201759/index.html

Opendata, web and dolomites

BIOFOSTE

Clinical validation of a BIOmarker panel For OSTEoarthritis diagnosis: BIOFOSTE

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

BIOFOSTE project word cloud

Explore the words cloud of the BIOFOSTE project. It provides you a very rough idea of what is the project "BIOFOSTE" about.

care panel sensitivity health articular tend found losses poor disease population opportunity select secondary cartilage standard age billions quantified disability purposes 40 combined commercialize correlated oa tens diagnostic degraded seizing final surgical elderly mirnas adults fact daily gold kit limit unproductivity irtal elisa leads biomarkers patented isolation mainly utility life osteoarthritis hospitalization cyanagen manifestations prognosis enter validate optimal marker normal diagnosis smes enhancer significantly joint extremely world business validation clinical test functional chemiluminescence burden degenerative outcome progression quality market ivd radiography middle decreasing absenteeism patients pain predict proteins altered economic depression clinicians

Project "BIOFOSTE" data sheet

The following table provides information about the project.

Coordinator	ISTITUTO DI RICERCA TRASLAZIONALE PER L'APPARATO LOCOMOTORE NICOLA CERULLI - LPMRI - SRL Organization address address: VIA A. EINSTEIN 12L city: AREZZO postcode: 52100 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Italy [IT]
Project website	http://www.irtal.com/
Total cost	71˙429 €
EC max contribution	50˙000 € (70%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-SMEINST-1-2015
Funding Scheme	SME-1
Starting year	2016
Duration (year-month-day)	from 2016-04-01 to 2016-09-30

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	ISTITUTO DI RICERCA TRASLAZIONALE PER L'APPARATO LOCOMOTORE NICOLA CERULLI - LPMRI - SRL ISTITUTO DI RICERCA TRASLAZIONALE PER L'APPARATO LOCOMOTORE NICOLA CERULLI - LPMRI - SRL Organization address address: VIA A. EINSTEIN 12L city: AREZZO postcode: 52100 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (AREZZO)	coordinator	50˙000.00
2	CYANAGEN SRL CYANAGEN SRL Organization address address: VIA DEGLI STRADELLI GUELFI 40/C city: BOLOGNA postcode: 40138 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (BOLOGNA)	participant	0.00

Map

Project objective

OSTEoarthritis (OA) is the most common degenerative joint disease in the middle-age and elderly population, that leads to disability in 40% of the adults over 70 years. The clinical manifestations of OA are pain and functional disability that can limit the normal activities of daily life and lead to depression and isolation. OA assessment is mainly carried out using radiography, which is the gold standard for diagnostic purposes. However this approach has poor sensitivity and diagnosis is obtained only when the articular cartilage has degraded significantly. Based on the extremely high economic burden, quantified in tens of billions of euro in the world, which will tend to increase in the future years, there is a need to validate OA biomarkers. In fact, although several proteins and miRNAs have been described as being altered and correlated with OA progression, there are no currently available BIOmarkers for OA diagnosis. This project concerns the development and clinical validation of a combined panel composed of proteins and miRNAs, which have been found altered in OA patients, combined with a new marker identified by IRTAL and a patented secondary chemiluminescence ELISA enhancer developed by CYANAGEN to ensure a high sensitivity for an early OA diagnosis. Our final goal is to validate and commercialize an IVD kit that may help the clinicians make an early diagnosis or predict the outcome/prognosis of OA patients, to improve the patients' quality of daily life while decreasing the related economic losses due to unproductivity, absenteeism, disability and also in terms of surgical procedures and hospitalization resources for the Health care systems. This project will allow involved SMEs to enter in the IVD market seizing the related business opportunity. In Phase 1 of the project we will select the optimal biomarkers, determine the market and clinical utility of the diagnostic test

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BIOFOSTE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BIOFOSTE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

RESHAPE (2019)

Reshaping undesired Inflammation in challenged Tissue Homeostasis by Next-Generation regulatory T cell (Treg) Approaches – from Advanced Technology Developments to First-in-Human Trials